Bacterioscan
Developer of a rapid, instrument-based diagnostic platform that uses laser light‑scattering to detect bacterial growth and profile urine specimens for urinary tract infection (UTI) status. The platform is cleared by the FDA for direct-from-urine rule-out of UTI, is intended for use in clinical laboratories and point-of-care settings, and is presented as a front-line screening tool to reduce culture volume and support antibiotic stewardship.
Industries
Nr. of Employees
small (1-50)
Bacterioscan
Patents
Products
Rapid UTI screening device (FDA‑cleared)
An instrumented diagnostic platform using laser light‑scattering to screen urine specimens for presence or absence of viable bacteria directly from urine samples and, in some workflows, to enable rapid phenotypic AST.
BacterioScan Microbial Growth Analyzer
Rapid laser microbial growth technology platform that detects infection and antibiotic resistance in 30-180 minutes.
BacterioScan
An FDA-cleared UTI detection device that uses light scattering technology to measure urine and broth turbidity in 30 to 180 minutes, ruling out urinary tract infections rapidly.
Rapid UTI screening device (FDA‑cleared)
An instrumented diagnostic platform using laser light‑scattering to screen urine specimens for presence or absence of viable bacteria directly from urine samples and, in some workflows, to enable rapid phenotypic AST.
BacterioScan Microbial Growth Analyzer
Rapid laser microbial growth technology platform that detects infection and antibiotic resistance in 30-180 minutes.
BacterioScan
An FDA-cleared UTI detection device that uses light scattering technology to measure urine and broth turbidity in 30 to 180 minutes, ruling out urinary tract infections rapidly.
Services
Requestable demos, implementation planning, and evaluation of workflow fit for clinical labs, health systems, physician offices, urgent care, and reference labs.
Requestable demos, implementation planning, and evaluation of workflow fit for clinical labs, health systems, physician offices, urgent care, and reference labs.
Expertise Areas
- Rapid diagnostic microbiology
- Phenotypic antimicrobial susceptibility testing
- Clinical performance validation
- Regulatory 510(k) pathway for diagnostics
Key Technologies
- Laser light‑scattering detection
- Forward/narrow‑angle laser light scattering (FLLS)
- Real‑time microbial growth monitoring
- Phenotypic antimicrobial susceptibility testing
News & Updates
Overview of antibiotic resistance and its impact on clinical care and UTI treatment; notes the potential value of rapid microbiology results to improve prescribing.
Discussion of inappropriate antibiotic use for UTIs and how rapid microbiology results can support antibiotic stewardship.
Performance summary comparing the rapid laser‑scattering screening method to quantitative urine culture for UTI detection.
Regulatory clearance enabling the device to be used to rule out urinary tract infection directly from urine samples.
Reported clinical performance across three U.S. hospital laboratories with sensitivity of 97.7% and negative predictive value of 99.2% for specimens at the defined threshold.
Overview of antibiotic resistance and its impact on clinical care and UTI treatment; notes the potential value of rapid microbiology results to improve prescribing.
Discussion of inappropriate antibiotic use for UTIs and how rapid microbiology results can support antibiotic stewardship.
Performance summary comparing the rapid laser‑scattering screening method to quantitative urine culture for UTI detection.
Regulatory clearance enabling the device to be used to rule out urinary tract infection directly from urine samples.
Reported clinical performance across three U.S. hospital laboratories with sensitivity of 97.7% and negative predictive value of 99.2% for specimens at the defined threshold.